Author | Lightnews

John Vandermosten @vanjohn10.bsky.social · 8h

Dr. Ann Childress, principal investigator on Cingulate’s CTx-1301 trials, highlights some of the differences in ADHD symptoms between children and adults.
#ADHD #Neuroscience #Biotech #SmallCapBiotech #BiotechInvesting #ClinicalPipeline #DrugDevelopment #NASDAQ

John Vandermosten @vanjohn10.bsky.social · 8h

Achieve Life Sciences CCO Jaime Xinos shares with investors how the marketing approach has changed with digital marketing making up a substantial proportion of the activities. She identifies some of the tools that are used to communicate with prescribers.
$ACHV
youtu.be/5jXTqdrdLPE
6

Commercialization is Evolving

YouTube video by Unboxing Biotech

youtu.be

John Vandermosten @vanjohn10.bsky.social · 3d

Cingulate's CTx-1301 selected for podium presentation @aacap.bsky.social Friday, 24Oct.
Presentation by Dr Ann Childress, PI on $CING clinical trials.
finance.yahoo.com/news/cingula...

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom controlKANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cin...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 3d

Rani Therapeutics appoints Abe Bassan & Vasudev Bailey, PhD to board representing new investors Samsara & Anomaly.
See Zacks' report for detail: s27.q4cdn.com/906368049/fi...
$RANI
finance.yahoo.com/news/rani-th...

s27.q4cdn.com

John Vandermosten @vanjohn10.bsky.social · 4d

Achieve Life Sciences CCO Jaime Xinos identifies the key areas where Omnicom's 8 different agencies will help with the commercialization effort. Some of these include public relations, marketing access & technology, & data analytics among other areas. $ACHV
youtu.be/joApmeZ_nMw

Omnicom 2

YouTube video by Unboxing Biotech

youtu.be

1

John Vandermosten @vanjohn10.bsky.social · 4d

Reviva Pharmaceuticals' #CEO Laxminarayan Bhat, Ph.D. shares examples of positive and negative symptoms in schizophrenia. #FDA
$RVPH
#schizophrenia #biopharma #biotech

John Vandermosten @vanjohn10.bsky.social · 4d

@lantheus.bsky.social to report 3Q on 6Nov
*8 am ET call
*webcast details in link
$LNTH
finance.yahoo.com/news/lantheu...

Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, No...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 4d

Spectral AI prices a $7.6mm offering to support DeepView efforts
$MDAI
finance.yahoo.com/news/spectra...

Spectral AI raises $7.6 Million of Additional Growth Capital

DALLAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more ...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 4d

Ligand Pharmaceuticals to report 3Q 6Nov
*8:30 am ET call
*Link includes dial in details
$LGND
finance.yahoo.com/news/ligand-...

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

JUPITER, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 20...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 5d

Dr Ann Childress, principal investigator on #Cingulate CTx-1301 trials, comments on an article that finds an association between use of ADHD medication and lower suicide risk.
$CING
www.bmj.com/content/390/...
#ADHD #Biotech #DrugDevelopment #ADHDTreatment #NASDAQ

John Vandermosten @vanjohn10.bsky.social · 5d

Today's the day! Azitra COO Travis Whitfill to present on the Dermatologic Rare Disease panel at Maxim Growth Summit
*8:30 am
*NYC
*Netherton syndrome & Recessive Epidermolysis Bullosa
Catch it while you can
$AZTR
ir.azitrainc.com/news-release...

Azitra to Participate in Dermatologic Rare Disease Panel at Maxim Growth Summit | Azitra, Inc.

BRANFORD, Conn. , Oct. 15, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...

ir.azitrainc.com

John Vandermosten @vanjohn10.bsky.social · 6d

Achieve Life Sciences appoints Erik Atkisson as Chief Legal Officer who will oversee $ACHV legal strategy, corporate governance, compliance, and risk management.
ir.achievelifesciences.com/news-events/...

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical…...

ir.achievelifesciences.com

John Vandermosten @vanjohn10.bsky.social · 6d

GeoVax highlights need for Mpox vaccine supply after 3 cases identified in California.
$GOVX
finance.yahoo.com/news/geovax-...

GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases

EMA Endorses Expedited Development Pathway for GEO-MVA; Company Advances U.S.-Based Continuous Cell Line Manufacturing to Address Fragile Supply Chains and Align With Federal Pandemic Preparedness Ini...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 6d

Achieve Life Sciences CEO Rick Stewart envisions a future where nicotine addiction is seen as a medical condition rather than a lifestyle choice.
$ACHV
youtu.be/-RucnhzdQYM

Parallels Between GLP-1s and Cytisinicline

YouTube video by Unboxing Biotech

youtu.be

1

John Vandermosten @vanjohn10.bsky.social · 6d

Achieve Life Sciences receives Commissioner's National Priority Voucher for its cytisinicline submission.
Could allow for expedited review of 1-2 months after all materials received.
$ACHV
ir.achievelifesciences.com/news-events/...

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only…...

ir.achievelifesciences.com

John Vandermosten @vanjohn10.bsky.social · 7d

Dr. Ann Childress, principal investigator on Cingulate's CTx-1301 trials, shares a story about ADHD medications that only work for part of the day.
$CING
#Cingulate #ADHD #Neuroscience #Biotech #BiotechStocks #LifeSciences #NASDAQ

John Vandermosten @vanjohn10.bsky.social · 7d

Radiopharm Theranostics completes A$35mm placement & announces A$5mm shares allocated towards existing investors. @lantheus.bsky.social makes a A$7.6mm investment. Includes warrants.
$RADX $LNTH
mcusercontent.com/2020b74e9b9a...

mcusercontent.com

John Vandermosten @vanjohn10.bsky.social · 9d

Dr. Ann Childress describes how the new #ADHD medication CTx-1301 works in this brief clip.
$CING
#Cingulate #Biotech #ClinicalTrials #LifeSciences #ADHDResearch #BiotechInvesting #PharmaNews #NASDAQ

John Vandermosten @vanjohn10.bsky.social · 10d

Rani Therapeutics $1B+ collab w/ Chugai Pharma for multiple indications in rare disease & immunology
*$10mm upfront
*$75mm tech xfer & dev milestones
*Option for 5 more drugs
*$60mm pvt placement also announced
$RANI
finance.yahoo.com/news/rani-th...

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurre...

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit ro...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 11d

FDA accepts Cingulate NDA for CTx-1301 in ADHD.
PDUFA date: 31May26.
$CING
finance.yahoo.com/news/fda-acc...

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS CITY, Kan...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 13d

Geovax execs David Dodd & John Sharkey to attend World Vaccine Congress Europe & BIO-Europe for partnering discussions. $GOVX will also visit with WHO, UNICEF, CEPI, Gavi & Africa CDC during the trip.
finance.yahoo.com/news/geovax-...

GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions

Executives to Participate at World Vaccine Congress Europe (Amsterdam, Oct 1316) and BIO-Europe Fall (Vienna, Nov 35), and Meet With NGOs, Industry Partners and Academic Collaborators ATLANTA, GA - Oc...

finance.yahoo.com

John Vandermosten @vanjohn10.bsky.social · 14d

Chief Commercial Officer Jaime Xinos explains Achieve Life Sciences’ strategy to deploy digital resources for maximum effect.
$ACHV
#SmokingCessation #ClinicalTrials #BiotechInnovation #LifeSciences #PublicHealth #AddictionResearch #TobaccoFreeFuture #HealthEquity #MedicalResearch #Biopharma

John Vandermosten @vanjohn10.bsky.social · 15d

Reviva Pharmaceuticals' #CEO Dr Bhat elaborates on brilaroxazine’s sustained efficacy and low discontinuation rate.
#schizophrenia #biopharma #biotech

John Vandermosten @vanjohn10.bsky.social · 16d

Achieve Life Sciences’ CEO Rick Stewart identifies varenicline side effects that may have led to discontinuation and compares with cytisinicline.
$ACHV
#SmokingCessation #ClinicalTrials #LifeSciences #AddictionResearch #TobaccoFreeFuture #HealthEquity #MedicalResearch #Biopharma

1

John Vandermosten @vanjohn10.bsky.social · 17d

where's the COVID button?